List of Excipients in Branded Drug CALCIUM DISODIUM VERSENATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health Us LLC	CALCIUM DISODIUM VERSENATE	edetate calcium disodium	99207-240	WATER

Calcium Disodium Versenate Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Calcium disodium versenate, also called edetate calcium disodium or calcium disodium EDTA, is an injectable chelating agent used primarily for lead poisoning. Its commercial opportunity is concentrated in hospital antidote supply, pediatric and emergency formulations, reliable manufacturing, and improved ready-to-administer packaging rather than in conventional mass-market volume.

The product has a mature active ingredient, limited apparent patent risk, and a narrow but strategically important market. Excipient selection is unusually constrained because calcium disodium EDTA can bind metal ions, alter electrolyte balance, and interact with formulation components, manufacturing equipment, and packaging materials.

What is calcium disodium versenate used for?

Calcium disodium versenate is an intravenous or intramuscular chelator that binds lead and promotes urinary excretion. The calcium in the molecule reduces the risk of severe hypocalcemia compared with disodium EDTA, which is not an appropriate substitute for lead poisoning treatment because it can cause dangerous calcium depletion. The product is used under medical supervision, often in children with significant lead exposure or patients requiring parenteral chelation.[1]

Attribute	Calcium disodium versenate
Active ingredient	Edetate calcium disodium
Common synonym	Calcium disodium EDTA
Therapeutic class	Heavy-metal chelating agent
Primary indication	Lead poisoning
Route	Intravenous or intramuscular
Typical dosage form	Sterile aqueous injection
Key safety issue	Nephrotoxicity and potential hypocalcemia
Principal customers	Hospitals, poison centers, emergency departments, government stockpiles
Main alternatives	Succimer, dimercaprol, penicillamine
Regulatory status	Prescription drug; product status varies by manufacturer and market

The drug is not a general nutritional EDTA product. Calcium disodium versenate should not be positioned as interchangeable with food-grade EDTA salts, sodium EDTA, or over-the-counter chelation products.

What excipients are used in calcium disodium versenate injection?

Approved formulations are generally simple aqueous systems. The core excipient strategy is typically water for injection, with sodium hydroxide used for pH adjustment where required by the product specification. The exact composition depends on the manufacturer, label, and presentation.

Formulation component	Commercial function	Key development issue
Water for injection	Primary vehicle	Must meet parenteral quality and endotoxin limits
Sodium hydroxide	pH adjustment	Excess alkalinity can increase tissue irritation and affect container compatibility
Container closure system	Sterility and stability barrier	Must limit extractables, leachables, and metal contamination
Nitrogen or other process control, if used	Oxygen reduction	Requires validation and cannot replace stability testing
No antimicrobial preservative, where applicable	Supports single-dose injectable use	Multidose positioning may create additional toxicology and compatibility burdens

A proposed formulation should not assume that common buffers are benign. Phosphate, citrate, acetate, and other ligand-containing excipients can affect metal-ion equilibria, pH, osmolality, or the availability of calcium and lead for chelation. These systems require laboratory assessment rather than routine formulation transfer from another injectable product.

Which excipients are technically risky for calcium disodium EDTA?

Metal contamination

Trace metals are a primary development concern. Calcium disodium EDTA is designed to bind metal ions, so stainless-steel contact surfaces, processing equipment, water systems, elastomers, pigments, and glass components can contribute extractable metals. The manufacturer should establish elemental impurity controls under ICH Q3D principles and evaluate metals that could compete with lead or alter product quality.[2]

Relevant controls include:

• Elemental impurity testing for raw materials and finished product.
• Qualification of stainless-steel equipment and contact parts.
• Assessment of glass delamination and container surface interactions.
• Control of copper, iron, zinc, aluminum, nickel, chromium, and other trace metals.
• Stability testing after exposure to manufacturing equipment and packaging.

Buffer selection

A minimally buffered formulation is generally attractive because it limits additional ligand interactions. If a buffer is required, the sponsor should assess:

• pH drift during storage.
• Calcium displacement.
• Chelation or complexation of trace metals.
• Precipitation at refrigerated and elevated temperatures.
• Compatibility with the intended injection route.
• Effect on osmolality and injection-site tolerability.

A formulation that is chemically stable but changes the free-calcium profile may create clinical and regulatory problems.

Preservatives

A preservative-free single-dose presentation is commercially defensible for an emergency injectable. Preservatives can complicate toxicology, compatibility, and pediatric use. Benzyl alcohol, phenol, parabens, and other antimicrobial agents should not be added solely to create a multidose product unless the commercial benefit justifies additional clinical and regulatory work.

Tonicity and pH

The final product must be evaluated for pH, osmolality, viscosity, injection volume, and local tolerability. Calcium disodium EDTA is administered in clinical settings where renal function, hydration, and electrolyte status are monitored. A formulation that increases hypertonicity or requires a high injection volume may reduce usability, especially in pediatric care.

What formulations are protected by patents?

No significant modern patent barrier is apparent for the basic calcium disodium EDTA injectable formulation. The active ingredient and conventional aqueous injection technology are mature. Any foundational composition or use patents associated with calcium disodium EDTA would be expected to have expired based on their age.

The relevant intellectual-property risk is more likely to arise from:

• A proprietary ready-to-use dilution.
• A premixed infusion bag.
• A novel container closure system.
• A stability-enhancing manufacturing process.
• A particular concentration or dosing presentation.
• A pediatric administration device.
• A combination or method-of-use claim involving a specific clinical protocol.

A sponsor should distinguish patent freedom to operate from regulatory exclusivity. The absence of a meaningful Orange Book patent listing would not eliminate the possibility of unlisted process, packaging, trade-secret, or foreign patent rights.

What is the Orange Book status of calcium disodium versenate?

The FDA Orange Book should be reviewed by product-specific application number and current marketing status because manufacturers and application holders can change over time.[3] For a mature injectable such as calcium disodium versenate, the commercial review should focus on:

1. Whether an active approved application remains listed.
2. Whether the product is marketed or discontinued.
3. Whether patents or regulatory exclusivity are listed.
4. Whether an ANDA applicant has an approved product.
5. Whether therapeutic-equivalence information is available.
6. Whether the reference product has been withdrawn for commercial reasons or safety reasons.

No meaningful period of modern New Chemical Entity exclusivity should be expected. Paragraph IV activity is therefore more likely to concern an improved formulation, a new dosage form, or a product-specific patent than the basic active ingredient.

When does calcium disodium versenate lose exclusivity?

The core molecule has long passed any conventional chemical-patent exclusivity period. The practical market barrier is supply and regulatory execution, not loss of exclusivity at a future date.

Exclusivity category	Commercial assessment
NCE exclusivity	Not relevant for this mature active ingredient
Basic composition patent	Expected to be expired
Conventional injectable formulation	Generally exposed to generic competition
Method-of-use patent	No major current barrier expected for standard lead-poisoning use
Orphan exclusivity	Not generally the primary commercial framework
Pediatric exclusivity	No current product-specific extension should be assumed
180-day generic exclusivity	Depends on the specific ANDA and Paragraph IV filing history
Data exclusivity	Expected to be immaterial for the mature product

The main launch risk is a deficient application, manufacturing interruption, sterile-product failure, or inability to maintain adequate inventory. Those issues can delay commercialization even when the intellectual-property landscape is open.

Which companies are challenging calcium disodium versenate?

The product has a small supplier base compared with common hospital injectables. Competitive activity may come from generic injectable manufacturers, specialty pharmaceutical companies, contract manufacturers, and firms supplying antidote portfolios.

A definitive list of current Paragraph IV challengers cannot be established from the drug name alone because the relevant filings are application-specific and may change. The key diligence sources are FDA Orange Book records, FDA approval announcements, ANDA litigation filings, and federal court dockets.[3,4]

For commercial purposes, the more relevant competitive question is whether another supplier can provide a dependable FDA-compliant sterile product in adequate quantities. The market may reward supply continuity more than marginal price reductions.

How strong is the patent estate for calcium disodium versenate?

The patent estate for the basic drug is weak from an exclusivity perspective but can still support targeted improvements.

IP category	Relative strength	Opportunity
Active ingredient	Low	Limited protection potential
Conventional aqueous injection	Low	Generic competition likely
Ready-to-use infusion	Moderate	Possible formulation and packaging claims
Pediatric delivery system	Moderate	Device and administration claims
Low-metal manufacturing process	Moderate	Process know-how and possible patent claims
Long-term stability package	Moderate	Packaging and formulation claims
Novel combination therapy	Unclear	Requires clinical and regulatory support
Trade secrets	Potentially high	Supplier qualification, process controls, and analytical methods

A company seeking defensible differentiation should focus on documented product performance and manufacturing controls. A broad patent strategy around calcium disodium EDTA itself is unlikely to produce durable protection.

What commercial opportunities exist for calcium disodium versenate?

Hospital antidote supply

Hospitals and poison centers need products that are available during rare but urgent toxicology events. A reliable supplier can compete through:

• Contracted hospital purchasing.
• Poison-center and regional health-system supply.
• Emergency department stocking.
• Government or public-health procurement.
• Minimum-stock and replenishment programs.
• Dual-site sterile manufacturing.

The small market does not eliminate commercial value. A shortage-prone antidote can command strategic importance because substitution is limited and treatment cannot be deferred easily.

Ready-to-use infusion presentations

Many injectable products require dilution before administration. A ready-to-use bag or pharmacy-ready presentation could reduce preparation time and compounding error, particularly in emergency settings.

Potential formats include:

• Premixed infusion bags.
• Small-volume pharmacy bulk packages.
• Unit-dose vials.
• Prefilled syringes for selected administration routes.
• Pediatric presentations with lower withdrawal volumes.

The development burden includes stability, container compatibility, extractables and leachables, sterility assurance, shipping validation, and labeling that clearly distinguishes the product from disodium EDTA.

Pediatric-focused packaging

Lead poisoning disproportionately affects children, making dose accuracy and handling important commercial variables. Opportunities include graduated containers, lower-volume vials, clear concentration labeling, and packaging that reduces calculation and withdrawal errors.

A pediatric strategy must avoid introducing preservatives or devices that create new safety concerns. Human-factors testing and dosing-error analysis can support differentiation even when the active ingredient is generic.

Supply-chain differentiation

The strongest commercial advantage may be operational:

• Multiple qualified API sources.
• Regional sterile fill-finish capacity.
• Secondary container suppliers.
• Validated cold-chain or controlled-room-temperature distribution.
• Safety-stock commitments.
• Transparent shortage communication.
• Lot-release testing for elemental impurities.

Because calcium disodium EDTA is a chelator, supplier qualification should cover metal contamination risks in addition to standard identity, potency, sterility, endotoxin, and particulate testing.

How does calcium disodium versenate compare with competing chelators?

Product	Route	Typical market role	Commercial distinction
Calcium disodium EDTA	IV or IM	Severe lead poisoning	Hospital injectable; calcium-containing chelator
Succimer	Oral	Lead poisoning in selected patients	More convenient outpatient route
Dimercaprol	IM	Severe heavy-metal poisoning, often combination therapy	Painful administration and broader toxicity burden
Penicillamine	Oral	Selected metal toxicities	Chronic-use option with tolerability and monitoring issues
Disodium EDTA	IV	Not an interchangeable lead-poisoning product	Hypocalcemia risk limits use

Calcium disodium versenate is most commercially defensible where parenteral treatment, rapid hospital access, or clinical severity makes an oral product unsuitable.

What regulatory pathway applies to a new product?

A generic calcium disodium EDTA injection would generally pursue an abbreviated new drug application if the reference product and dosage form support that pathway. A materially different presentation, such as a novel ready-to-use infusion or new delivery system, may require additional pharmaceutical equivalence, bioequivalence, stability, device, or clinical justification.

The regulatory package should address:

• Active-ingredient identity and assay.
• Sterility and bacterial endotoxins.
• Particulate matter.
• pH and osmolality.
• Elemental impurities.
• Container-closure integrity.
• Extractables and leachables.
• In-use and dilution stability.
• Compatibility with infusion materials.
• Labeling that distinguishes calcium disodium EDTA from disodium EDTA.
• Renal and electrolyte safety information.

FDA labeling emphasizes that treatment requires medical supervision and appropriate monitoring, particularly because renal toxicity and electrolyte abnormalities are clinically important.[1]

What generic launch risks exist?

The likely launch scenarios are:

Scenario	Probability profile	Commercial result
Single generic entrant	Moderate	Strong pricing if supply is reliable
Multiple generic entrants	Moderate	Lower price and inventory-based competition
Shortage-driven launch	Material	Rapid uptake but procurement volatility
Ready-to-use differentiated product	Selective	Premium pricing if preparation burden falls
Manufacturing interruption	Material	Loss of contracts and regulatory scrutiny
Competing oral chelator substitution	Limited	Depends on clinical severity and patient setting

The principal risks are sterile manufacturing failure, inconsistent availability, insufficient hospital demand forecasting, inadequate pediatric usability, and confusion with disodium EDTA.

Key Takeaways

• Calcium disodium versenate is a mature injectable chelator for lead poisoning with limited basic patent risk.
• The active ingredient is not the main source of commercial differentiation.
• Excipients should be minimized and selected with attention to metal binding, calcium balance, pH, osmolality, and container compatibility.
• Preservative-free, single-dose aqueous presentations are commercially logical for emergency and pediatric use.
• Ready-to-use bags, pediatric packaging, and reliable supply may support premium positioning.
• Orange Book and Paragraph IV analysis must be performed by specific application and manufacturer because product status changes over time.
• The strongest practical barriers are sterile manufacturing, elemental impurity control, regulatory compliance, and dependable inventory.
• Competitive products include succimer, dimercaprol, penicillamine, and disodium EDTA, but these products are not clinically interchangeable in all settings.
• A successful commercial strategy should combine a simple formulation with superior supply continuity, packaging, and hospital procurement execution.

FAQs

Is calcium disodium versenate the same as disodium EDTA?

No. Calcium disodium EDTA is used for lead poisoning and contains calcium. Disodium EDTA can produce dangerous hypocalcemia and is not an interchangeable treatment for lead poisoning.

Can calcium disodium EDTA be formulated with phosphate buffer?

It may be possible, but phosphate requires compatibility, pH, calcium-equilibrium, precipitation, and stability testing. A minimally buffered formulation is generally easier to justify.

Is there an opportunity for an oral calcium disodium EDTA product?

An oral product would face absorption, tolerability, bioavailability, and clinical-performance questions. The established competitive benchmark for oral lead chelation is succimer, which would make a new oral calcium disodium EDTA product commercially difficult to differentiate.

What is the best packaging strategy for hospitals?

A preservative-free unit-dose vial is a practical baseline. A ready-to-use infusion bag or pediatric dose presentation may provide greater differentiation if stability, container compatibility, and procurement demand support the additional development cost.

Can a calcium disodium EDTA manufacturer obtain new patent protection?

Potentially, but protection would most likely relate to a novel formulation, delivery system, packaging configuration, manufacturing process, or stability solution rather than the mature active ingredient itself.

References

1. U.S. Food and Drug Administration. (n.d.). Calcium disodium versenate injection prescribing information. FDA-approved product labeling.

2. International Council for Harmonisation. (2022). ICH Q3D(R2): Guideline for elemental impurities. ICH.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.

4. U.S. Food and Drug Administration. (n.d.). FDA drug shortages database. FDA.

5. DailyMed. (n.d.). Edetate calcium disodium injection product labeling. National Library of Medicine.